PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000019

Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany

Identifieur interne : 000019 ( PascalFrancis/Corpus ); précédent : 000018; suivant : 000020

Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany

Auteurs : Jürgen Prestel ; Peter Volkers ; Dirk Mentzer ; Helmar C. Lehmann ; Hans-Peter Hartung ; Brigitte Keller-Stanislawski

Source :

Pharmacoepidemiology and drug safety [ 1053-8569 ] ; 2014.

RBID : Pascal:14-0279354

Descripteurs français

Pascal (Inist)
- Facteur risque, Polyradiculonévrite de Guillain-Barré, Grippe A, Vaccination, Prévention, Allemagne, Epidémiologie, Médicament, Pharmacovigilance, Efficacité traitement, Grippe pandémique, Pharmacoépidémiologie, Grippe H1N1.

English descriptors

KwdEn :
- Drug, Epidemiology, Germany, Guillain-Barré syndrome, H1N1 influenza, Influenza A, Pharmacovigilance, Prevention, Risk factor, Treatment efficiency, Vaccination.

Abstract

Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1053-8569`
A02	`01`			`@0 PDSAEA`
A03		`1`		`@0 Pharmacoepidemiol. drug saf.`
A05				`@2 23`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany`
A11	`01`	`1`		`@1 PRESTEL (Jürgen)`
A11	`02`	`1`		`@1 VOLKERS (Peter)`
A11	`03`	`1`		`@1 MENTZER (Dirk)`
A11	`04`	`1`		`@1 LEHMANN (Helmar C.)`
A11	`05`	`1`		`@1 HARTUNG (Hans-Peter)`
A11	`06`	`1`		`@1 KELLER-STANISLAWSKI (Brigitte)`
A14	`01`			`@1 Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines @2 Langen @3 DEU @Z 1 aut. @Z 3 aut. @Z 6 aut.`
A14	`02`			`@1 Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines @2 Langen @3 DEU @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Heinrich-Heine-University Düsseldorf @2 Düsseldorf @3 DEU @Z 4 aut. @Z 5 aut.`
A14	`04`			`@1 Department of Neurology, University Hospital of Cologne @2 Cologne @3 DEU @Z 4 aut.`
A17	`01`	`1`		`@1 GBS Study Group @3 INC`
A20				`@1 1192-1204`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27568 @5 354000502503730110`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 44 ref.`
A47	`01`	`1`		`@0 14-0279354`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Pharmacoepidemiology and drug safety`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.
C02	`01`	`X`		`@0 002B02A06`
C02	`02`	`X`		`@0 002B17F`
C02	`03`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Facteur risque @5 01`
C03	`01`	`X`	`ENG`	`@0 Risk factor @5 01`
C03	`01`	`X`	`SPA`	`@0 Factor riesgo @5 01`
C03	`02`	`X`	`FRE`	`@0 Polyradiculonévrite de Guillain-Barré @5 02`
C03	`02`	`X`	`ENG`	`@0 Guillain-Barré syndrome @5 02`
C03	`02`	`X`	`SPA`	`@0 Polirradiculoneuritis Guillain-Barré @5 02`
C03	`03`	`X`	`FRE`	`@0 Grippe A @5 03`
C03	`03`	`X`	`ENG`	`@0 Influenza A @5 03`
C03	`03`	`X`	`SPA`	`@0 Gripe A @5 03`
C03	`04`	`X`	`FRE`	`@0 Vaccination @5 04`
C03	`04`	`X`	`ENG`	`@0 Vaccination @5 04`
C03	`04`	`X`	`SPA`	`@0 Vacunación @5 04`
C03	`05`	`X`	`FRE`	`@0 Prévention @5 05`
C03	`05`	`X`	`ENG`	`@0 Prevention @5 05`
C03	`05`	`X`	`SPA`	`@0 Prevención @5 05`
C03	`06`	`X`	`FRE`	`@0 Allemagne @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 Germany @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Alemania @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Epidémiologie @5 07`
C03	`07`	`X`	`ENG`	`@0 Epidemiology @5 07`
C03	`07`	`X`	`SPA`	`@0 Epidemiología @5 07`
C03	`08`	`X`	`FRE`	`@0 Médicament @5 08`
C03	`08`	`X`	`ENG`	`@0 Drug @5 08`
C03	`08`	`X`	`SPA`	`@0 Medicamento @5 08`
C03	`09`	`X`	`FRE`	`@0 Pharmacovigilance @5 09`
C03	`09`	`X`	`ENG`	`@0 Pharmacovigilance @5 09`
C03	`09`	`X`	`SPA`	`@0 Farmacovigilancia @5 09`
C03	`10`	`X`	`FRE`	`@0 Efficacité traitement @5 10`
C03	`10`	`X`	`ENG`	`@0 Treatment efficiency @5 10`
C03	`10`	`X`	`SPA`	`@0 Eficacia tratamiento @5 10`
C03	`11`	`X`	`FRE`	`@0 Grippe pandémique @4 INC @5 86`
C03	`12`	`X`	`FRE`	`@0 Pharmacoépidémiologie @4 INC @5 87`
C03	`13`	`X`	`FRE`	`@0 Grippe H1N1 @4 CD @5 96`
C03	`13`	`X`	`ENG`	`@0 H1N1 influenza @4 CD @5 96`
C03	`13`	`X`	`SPA`	`@0 Gripe H1N1 @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Europe @2 NG`
C07	`03`	`X`	`ENG`	`@0 Europe @2 NG`
C07	`03`	`X`	`SPA`	`@0 Europa @2 NG`
C07	`04`	`X`	`FRE`	`@0 Maladie inflammatoire @5 37`
C07	`04`	`X`	`ENG`	`@0 Inflammatory disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Enfermedad inflamatoria @5 37`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux périphérique @5 38`
C07	`05`	`X`	`ENG`	`@0 Peripheral nerve disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Nervio periférico patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 39`
C07	`06`	`X`	`ENG`	`@0 Nervous system diseases @5 39`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 40`
C07	`07`	`X`	`ENG`	`@0 Respiratory disease @5 40`
C07	`07`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 40`
N21				`@1 349`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0279354 INIST
ET :	Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany
AU :	PRESTEL (Jürgen); VOLKERS (Peter); MENTZER (Dirk); LEHMANN (Helmar C.); HARTUNG (Hans-Peter); KELLER-STANISLAWSKI (Brigitte)
AF :	Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines/Langen/Allemagne (1 aut., 3 aut., 6 aut.); Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines/Langen/Allemagne (2 aut.); Department of Neurology, Heinrich-Heine-University Düsseldorf/Düsseldorf/Allemagne (4 aut., 5 aut.); Department of Neurology, University Hospital of Cologne/Cologne/Allemagne (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Pharmacoepidemiology and drug safety; ISSN 1053-8569; Coden PDSAEA; Royaume-Uni; Da. 2014; Vol. 23; No. 11; Pp. 1192-1204; Bibl. 44 ref.
LA :	Anglais
EA :	Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.
CC :	002B02A06; 002B17F; 002B05C02C
FD :	Facteur risque; Polyradiculonévrite de Guillain-Barré; Grippe A; Vaccination; Prévention; Allemagne; Epidémiologie; Médicament; Pharmacovigilance; Efficacité traitement; Grippe pandémique; Pharmacoépidémiologie; Grippe H1N1
FG :	Virose; Infection; Europe; Maladie inflammatoire; Pathologie du système nerveux périphérique; Pathologie du système nerveux; Pathologie de l'appareil respiratoire
ED :	Risk factor; Guillain-Barré syndrome; Influenza A; Vaccination; Prevention; Germany; Epidemiology; Drug; Pharmacovigilance; Treatment efficiency; H1N1 influenza
EG :	Viral disease; Infection; Europe; Inflammatory disease; Peripheral nerve disease; Nervous system diseases; Respiratory disease
SD :	Factor riesgo; Polirradiculoneuritis Guillain-Barré; Gripe A; Vacunación; Prevención; Alemania; Epidemiología; Medicamento; Farmacovigilancia; Eficacia tratamiento; Gripe H1N1
LO :	INIST-27568.354000502503730110
ID :	14-0279354

Links to Exploration step

Pascal:14-0279354

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany</title>
<author><name sortKey="Prestel, Jurgen" sort="Prestel, Jurgen" uniqKey="Prestel J" first="Jürgen" last="Prestel">Jürgen Prestel</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Volkers, Peter" sort="Volkers, Peter" uniqKey="Volkers P" first="Peter" last="Volkers">Peter Volkers</name>
<affiliation><inist:fA14 i1="02"><s1>Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mentzer, Dirk" sort="Mentzer, Dirk" uniqKey="Mentzer D" first="Dirk" last="Mentzer">Dirk Mentzer</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lehmann, Helmar C" sort="Lehmann, Helmar C" uniqKey="Lehmann H" first="Helmar C." last="Lehmann">Helmar C. Lehmann</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Heinrich-Heine-University Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University Hospital of Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartung, Hans Peter" sort="Hartung, Hans Peter" uniqKey="Hartung H" first="Hans-Peter" last="Hartung">Hans-Peter Hartung</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Heinrich-Heine-University Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Keller Stanislawski, Brigitte" sort="Keller Stanislawski, Brigitte" uniqKey="Keller Stanislawski B" first="Brigitte" last="Keller-Stanislawski">Brigitte Keller-Stanislawski</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0279354</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0279354 INIST</idno>
<idno type="RBID">Pascal:14-0279354</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany</title>
<author><name sortKey="Prestel, Jurgen" sort="Prestel, Jurgen" uniqKey="Prestel J" first="Jürgen" last="Prestel">Jürgen Prestel</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Volkers, Peter" sort="Volkers, Peter" uniqKey="Volkers P" first="Peter" last="Volkers">Peter Volkers</name>
<affiliation><inist:fA14 i1="02"><s1>Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mentzer, Dirk" sort="Mentzer, Dirk" uniqKey="Mentzer D" first="Dirk" last="Mentzer">Dirk Mentzer</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lehmann, Helmar C" sort="Lehmann, Helmar C" uniqKey="Lehmann H" first="Helmar C." last="Lehmann">Helmar C. Lehmann</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Heinrich-Heine-University Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University Hospital of Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartung, Hans Peter" sort="Hartung, Hans Peter" uniqKey="Hartung H" first="Hans-Peter" last="Hartung">Hans-Peter Hartung</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Heinrich-Heine-University Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Keller Stanislawski, Brigitte" sort="Keller Stanislawski, Brigitte" uniqKey="Keller Stanislawski B" first="Brigitte" last="Keller-Stanislawski">Brigitte Keller-Stanislawski</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Pharmacoepidemiology and drug safety</title>
<title level="j" type="abbreviated">Pharmacoepidemiol. drug saf.</title>
<idno type="ISSN">1053-8569</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Pharmacoepidemiology and drug safety</title>
<title level="j" type="abbreviated">Pharmacoepidemiol. drug saf.</title>
<idno type="ISSN">1053-8569</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Drug</term>
<term>Epidemiology</term>
<term>Germany</term>
<term>Guillain-Barré syndrome</term>
<term>H1N1 influenza</term>
<term>Influenza A</term>
<term>Pharmacovigilance</term>
<term>Prevention</term>
<term>Risk factor</term>
<term>Treatment efficiency</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term>
<term>Polyradiculonévrite de Guillain-Barré</term>
<term>Grippe A</term>
<term>Vaccination</term>
<term>Prévention</term>
<term>Allemagne</term>
<term>Epidémiologie</term>
<term>Médicament</term>
<term>Pharmacovigilance</term>
<term>Efficacité traitement</term>
<term>Grippe pandémique</term>
<term>Pharmacoépidémiologie</term>
<term>Grippe H1N1</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1053-8569</s0>
</fA01>
<fA02 i1="01"><s0>PDSAEA</s0>
</fA02>
<fA03 i2="1"><s0>Pharmacoepidemiol. drug saf.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PRESTEL (Jürgen)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>VOLKERS (Peter)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MENTZER (Dirk)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEHMANN (Helmar C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HARTUNG (Hans-Peter)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KELLER-STANISLAWSKI (Brigitte)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines</s1>
<s2>Langen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Heinrich-Heine-University Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, University Hospital of Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>GBS Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>1192-1204</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27568</s2>
<s5>354000502503730110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0279354</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Pharmacoepidemiology and drug safety</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02A06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Polyradiculonévrite de Guillain-Barré</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Guillain-Barré syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Polirradiculoneuritis Guillain-Barré</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Grippe A</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Influenza A</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Gripe A</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Prévention</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prevention</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Prevención</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Allemagne</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Germany</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Alemania</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Médicament</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Drug</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pharmacovigilance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Pharmacovigilance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Farmacovigilancia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Grippe pandémique</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pharmacoépidémiologie</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Grippe H1N1</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>H1N1 influenza</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Gripe H1N1</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie inflammatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Inflammatory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux périphérique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Peripheral nerve disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Nervio periférico patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>349</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0279354 INIST</NO>
<ET>Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany</ET>
<AU>PRESTEL (Jürgen); VOLKERS (Peter); MENTZER (Dirk); LEHMANN (Helmar C.); HARTUNG (Hans-Peter); KELLER-STANISLAWSKI (Brigitte)</AU>
<AF>Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines/Langen/Allemagne (1 aut., 3 aut., 6 aut.); Division of EU Co-operation/Microbiology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines/Langen/Allemagne (2 aut.); Department of Neurology, Heinrich-Heine-University Düsseldorf/Düsseldorf/Allemagne (4 aut., 5 aut.); Department of Neurology, University Hospital of Cologne/Cologne/Allemagne (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Pharmacoepidemiology and drug safety; ISSN 1053-8569; Coden PDSAEA; Royaume-Uni; Da. 2014; Vol. 23; No. 11; Pp. 1192-1204; Bibl. 44 ref.</SO>
<LA>Anglais</LA>
<EA>Purpose A prospective, epidemiologic study was conducted to assess whether the 2009 pandemic influenza A(H1N1) vaccination in Germany almost exclusively using an AS03-adjuvanted vaccine (Pandemrix) impacts the risk of Guillain-Barré syndrome (GBS) and its variant Fisher syndrome (FS). Methods Potential cases of GBS/FS were reported by 351 participating hospitals throughout Germany. The self-controlled case series methodology was applied to all GBS/FS cases fulfilling the Brighton Collaboration (BC) case definition (levels 1-3 of diagnostic certainty) with symptom onset between 1 November 2009 and 30 September 2010 reported until end of December 2010. Results Out of 676 GBS/FS reports, in 30 cases, GBS/FS (BC levels 1-3) occurred within 150 days following influenza A(H1N1) vaccination. The relative incidence of GBS/FS within the primary risk period (days 5-42 post-vaccination) compared with the control period (days 43-150 post-vaccination) was 4.65 (95%CI [2.17, 9.98]). Similar results were found when stratifying for infections within 3 weeks prior to onset of GBS/ FS and when excluding cases with additional seasonal influenza vaccination. The overall result of temporally adjusted analyses supported the primary finding of an increased relative incidence of GBS/FS following influenza A(H1N1) vaccination. Conclusions The results indicate an increased risk of GBS/FS in temporal association with pandemic influenza A(H1N1) vaccination in Germany.</EA>
<CC>002B02A06; 002B17F; 002B05C02C</CC>
<FD>Facteur risque; Polyradiculonévrite de Guillain-Barré; Grippe A; Vaccination; Prévention; Allemagne; Epidémiologie; Médicament; Pharmacovigilance; Efficacité traitement; Grippe pandémique; Pharmacoépidémiologie; Grippe H1N1</FD>
<FG>Virose; Infection; Europe; Maladie inflammatoire; Pathologie du système nerveux périphérique; Pathologie du système nerveux; Pathologie de l'appareil respiratoire</FG>
<ED>Risk factor; Guillain-Barré syndrome; Influenza A; Vaccination; Prevention; Germany; Epidemiology; Drug; Pharmacovigilance; Treatment efficiency; H1N1 influenza</ED>
<EG>Viral disease; Infection; Europe; Inflammatory disease; Peripheral nerve disease; Nervous system diseases; Respiratory disease</EG>
<SD>Factor riesgo; Polirradiculoneuritis Guillain-Barré; Gripe A; Vacunación; Prevención; Alemania; Epidemiología; Medicamento; Farmacovigilancia; Eficacia tratamiento; Gripe H1N1</SD>
<LO>INIST-27568.354000502503730110</LO>
<ID>14-0279354</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000019 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0279354
   |texte=   Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany

Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri